Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

OPKO Health

DB:XCY
Snowflake Description

Reasonable growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XCY
DB
$851M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • OPKO Health has significant price volatility in the past 3 months.
XCY Share Price and Events
7 Day Returns
6.3%
DB:XCY
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-48.9%
DB:XCY
-7.4%
DE Biotechs
-14.2%
DE Market
XCY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OPKO Health (XCY) 6.3% -39.7% -10.4% -48.9% -83.2% -91.7%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • XCY underperformed the Biotechs industry which returned -7.4% over the past year.
  • XCY underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
XCY
Industry
5yr Volatility vs Market
Related Companies

Value

 Is OPKO Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of OPKO Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for OPKO Health.

DB:XCY Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:XCY
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (37.14%))
1.238
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.24
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.238 * 5.44%)
6.35%

Discounted Cash Flow Calculation for DB:XCY using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for OPKO Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:XCY DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.35%)
2020 -92.20 Analyst x1 -86.70
2021 -40.40 Analyst x1 -35.72
2022 27.50 Analyst x1 22.86
2023 116.00 Analyst x1 90.69
2024 221.60 Analyst x1 162.91
2025 310.43 Est @ 40.09% 214.60
2026 397.17 Est @ 27.94% 258.18
2027 474.39 Est @ 19.44% 289.97
2028 538.40 Est @ 13.49% 309.46
2029 588.62 Est @ 9.33% 318.14
Present value of next 10 years cash flows $1,544.00
DB:XCY DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $588.62 × (1 + -0.39%) ÷ (6.35% – -0.39%)
$8,704.02
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $8,704.02 ÷ (1 + 6.35%)10
$4,704.33
DB:XCY Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,544.00 + $4,704.33
$6,248.33
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,248.33 / 669.83
$9.33
DB:XCY Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:XCY represents 0.84187x of NasdaqGS:OPK
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.84187x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 9.33 x 0.84187
€7.85
Value per share (EUR) From above. €7.85
Current discount Discount to share price of €1.17
= -1 x (€1.17 - €7.85) / €7.85
85.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price OPKO Health is available for.
Intrinsic value
>50%
Share price is €1.17 vs Future cash flow value of €7.85
Current Discount Checks
For OPKO Health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • OPKO Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • OPKO Health's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OPKO Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OPKO Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:XCY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.53
NasdaqGS:OPK Share Price ** NasdaqGS (2020-04-08) in USD $1.39
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OPKO Health.

DB:XCY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:OPK Share Price ÷ EPS (both in USD)

= 1.39 ÷ -0.53

-2.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OPKO Health is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OPKO Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OPKO Health's expected growth come at a high price?
Raw Data
DB:XCY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
40.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OPKO Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OPKO Health's assets?
Raw Data
DB:XCY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.41
NasdaqGS:OPK Share Price * NasdaqGS (2020-04-08) in USD $1.39
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:XCY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:OPK Share Price ÷ Book Value per Share (both in USD)

= 1.39 ÷ 2.41

0.58x

* Primary Listing of OPKO Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OPKO Health is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OPKO Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OPKO Health has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OPKO Health expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OPKO Health expected to grow at an attractive rate?
  • OPKO Health's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • OPKO Health's earnings growth is expected to exceed the Germany market average.
  • OPKO Health's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:XCY Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:XCY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 40.6%
DB:XCY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 8.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:XCY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:XCY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,344 16 3
2023-12-31 1,181 -67 3
2022-12-31 1,044 -129 3
2021-12-31 976 -168 5
2020-12-31 886 -235 5
2020-04-08
DB:XCY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 902 -173 -315
2019-09-30 899 -161 -279
2019-06-30 920 -159 -244
2019-03-31 958 -123 -191
2018-12-31 990 -109 -153
2018-09-30 929 -72 -295
2018-06-30 926 -88 -303
2018-03-31 955 -94 -314
2017-12-31 966 -92 -305
2017-09-30 1,081 -64 -101
2017-06-30 1,133 -58 -80
2017-03-31 1,197 7 -48

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OPKO Health's earnings are expected to grow significantly at over 20% yearly.
  • OPKO Health's revenue is expected to grow by 8.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:XCY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from OPKO Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XCY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.03 0.11 -0.09 3.00
2023-12-31 -0.10 -0.04 -0.14 3.00
2022-12-31 -0.19 -0.16 -0.23 3.00
2021-12-31 -0.26 -0.10 -0.40 4.00
2020-12-31 -0.37 -0.32 -0.39 5.00
2020-04-08
DB:XCY Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.53
2019-09-30 -0.48
2019-06-30 -0.42
2019-03-31 -0.33
2018-12-31 -0.27
2018-09-30 -0.53
2018-06-30 -0.54
2018-03-31 -0.56
2017-12-31 -0.55
2017-09-30 -0.18
2017-06-30 -0.14
2017-03-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OPKO Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OPKO Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OPKO Health has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OPKO Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OPKO Health's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OPKO Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare OPKO Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OPKO Health's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OPKO Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OPKO Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XCY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 901.94 -314.93 327.71 53.37
2019-09-30 899.45 -278.65 373.28 40.05
2019-06-30 920.49 -244.29 376.81 38.38
2019-03-31 957.80 -190.69 375.99 36.71
2018-12-31 990.27 -153.04 353.45 53.33
2018-09-30 929.40 -294.88 372.27 27.12
2018-06-30 925.62 -303.15 391.38 70.22
2018-03-31 954.54 -313.86 409.30 36.78
2017-12-31 966.01 -305.25 408.83 53.51
2017-09-30 1,080.51 -101.00 458.03 43.15
2017-06-30 1,132.50 -80.06 479.00 39.98
2017-03-31 1,197.01 -47.61 490.93 40.15
2016-12-31 1,117.49 -48.36 408.23 40.63
2016-09-30 1,222.36 -9.82 463.21 42.12
2016-06-30 1,067.36 133.40 394.31 41.53
2016-03-31 752.69 75.11 297.73 44.19
2015-12-31 491.74 -30.03 204.38 43.72
2015-09-30 241.08 -84.60 111.47 52.61
2015-06-30 117.82 -261.52 70.24 49.46
2015-03-31 98.94 -244.23 64.17 43.32
2014-12-31 91.13 -171.67 60.54 41.02
2014-09-30 86.28 -135.50 60.04 41.81
2014-06-30 87.15 -146.82 59.60 39.40
2014-03-31 87.43 -124.74 58.61 36.10
2013-12-31 96.53 -114.83 57.22 34.31
2013-09-30 92.10 -99.06 50.24 31.19
2013-06-30 83.25 -49.45 43.99 27.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OPKO Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OPKO Health has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OPKO Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OPKO Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OPKO Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OPKO Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OPKO Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OPKO Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OPKO Health's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of OPKO Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OPKO Health Company Filings, last reported 3 months ago.

DB:XCY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,614.76 269.48 85.45
2019-09-30 1,641.93 270.62 64.67
2019-06-30 1,708.93 287.02 111.12
2019-03-31 1,762.74 320.35 207.25
2018-12-31 1,791.29 204.56 96.47
2018-09-30 1,788.64 199.07 43.72
2018-06-30 1,810.50 199.95 80.38
2018-03-31 1,823.26 198.44 99.94
2017-12-31 1,843.62 146.81 91.50
2017-09-30 2,089.04 139.18 100.36
2017-06-30 2,106.83 120.51 130.53
2017-03-31 2,106.97 91.52 131.05
2016-12-31 2,091.81 95.21 168.73
2016-09-30 2,105.39 102.12 144.65
2016-06-30 2,015.64 95.50 171.65
2016-03-31 1,997.87 135.77 174.97
2015-12-31 1,979.79 135.08 193.60
2015-09-30 1,969.37 127.45 212.14
2015-06-30 826.99 125.95 221.22
2015-03-31 812.57 122.46 348.19
2014-12-31 835.74 147.34 96.91
2014-09-30 887.34 129.96 118.26
2014-06-30 912.83 133.71 134.01
2014-03-31 831.25 238.93 156.40
2013-12-31 872.98 227.74 185.80
2013-09-30 867.93 226.74 180.84
2013-06-30 312.48 208.94 169.09
  • OPKO Health's level of debt (16.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (17.6% vs 16.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OPKO Health has less than a year of cash runway based on current free cash flow.
  • OPKO Health has less than a year of cash runway if free cash flow continues to grow at historical rates of 29.8% each year.
X
Financial health checks
We assess OPKO Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OPKO Health has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OPKO Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OPKO Health dividends.
If you bought €2,000 of OPKO Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OPKO Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OPKO Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:XCY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:XCY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OPKO Health has not reported any payouts.
  • Unable to verify if OPKO Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OPKO Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OPKO Health has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OPKO Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OPKO Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OPKO Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OPKO Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Phil Frost
COMPENSATION $2,036,000
AGE 83
TENURE AS CEO 13.1 years
CEO Bio

Dr. Phillip Frost, also known as Phil, M.D., Ph.D., has been Chief Executive Officer of Opko Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and General Partner of Frost Phillip MD Et Al. He serves as General Partner at Frost Group, LLC, Frost Group LLC and Incentive 2 Management Inc. (Alternate Name: Incentive Management Inc.). He also serves as Chief Executive Officer of Opko Health Inc. at Claros Diagnostics, Inc. He is also employed at MBF Healthcare Partners, L.P. He served as a Special Advisor of Castle Brands Inc. He served as a General Partner of Peregrine Ventures. He served as the Chief Executive Officer of eXegenics Inc. He served as the Chief Executive Officer of IVAX Corporation. He served as Chief Executive Officer from 1987 to January 26, 2006 and served as its President from July 1991 to January 1995 at IVAX LLC. He served as Lieutenant Commander in the U.S. Public Health Service at the National Cancer Institute, in Bethesda, Maryland from 1963 to 1965. He served as Chief Executive Officer at Teva Pharmaceutical Industries in 1987. He has been the Chairman of Opko Health, Inc. since March 27, 2007. He has been the Chairman of OPKO Biologics since March 2008. He serves as the Chairman of the Board of Non-Invasive Monitoring Systems Inc. He serves as the Chairman of Temple Emanu El. He serves as the Chairman of Medical Advisory Board of Daxor Corporation. He has been the Chairman of Strategic Advisory Board and Member of Strategic Advisory Board at Drone Aviation Holding Corp. since August 28, 2014. He serves as the Chairman of University of Miami. Dr. Frost is a Co-Owner at Frost Gamma Investments Trust. He serves as Vice Chairman at IDI, Inc. He has been a Director of Cocrystal Pharma, Inc. since January 2, 2014 and OPKO Biologics since May 2007. He serves as a Director at Non-Invasive Monitoring Systems Inc. He has been a Senior Trustee of University of Miami since 1983. He serves as a Member of Advisory Board at Non-Invasive Monitoring Systems Inc. He serves as a Director of Fabrus, Inc. and The Center for Blood Research Inc., an affiliate of the Harvard Medical School. He has been a Director of IDI, Inc. since December 8, 2015, Opko Health, Inc. since March 27, 2007 and Independent Director of Sevion Therapeutics, Inc. (formerly Senesco Technologies, Inc.) since May 2014. He serves as a Governor of Tel Aviv University. He also serves as a Member of the Florida Council of 100. He serves as a Trustee of each of the Scripps Research Institutes, the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He was a Director of Ladenburg Thalmann Financial Services Inc., since March 2004 until September 20, 2018. He served as Chairman at Ladenburg Thalmann Financial Services Inc. since July 2006 until September 20, 2018. He serves as Chairman and Director at Claros Diagnostics, Inc. He served as the Chairman and Director of Ideation Acquisition Corp. from June 1, 2007 to October 30, 2009, ERBA Diagnostics, Inc. from March 2001 to April 2006, IVAX Corporation since 1987 and Key Pharmaceutical Inc., from 1972 to 1986. He served as the Chairman and Director of Whitman Education Group, Inc. from 1992 to 2003. Dr. Frost served as the Chairman of Key Pharmaceuticals, Inc. from 1972 to 1986. He served as the Chairman and Director of IVAX Diagnostics Inc. He served as the Chairman of Teva Pharmaceutical Industries Limited from March 2010 to December 31, 2014. He served as an Executive Vice Chairman and Director at Tiger Media, Inc. since December 9, 2015. He served as Vice Chairman of Teva Pharmaceutical Industries Limited from January 2006 to March 2010. He served as a Co-Vice Chairman of NYSE MKT LLC since April 2005 and served as its Governor. He served as a Co-Vice Chairman of American Stock Exchange LLC from April 2005 to 2008 and its Governor from 1992 to 2008. He served as the Chairman of the Board of Continucare Corporation from September 1996 to April 2002, Pan Am Corporation since April 16, 1996 and North American Vaccine from December 1990 to 2000. He served as a Director at Ladenburg Thalmann Financial Services Inc. from May 2001 to July 2002. He served as Director from September 2005 to September 12, 2007. He served as a Director at Castle Brands Inc. since October 2008 until October 9, 2019. He served as a Member of Scientific Advisory Board at MusclePharm Corporation. He served as an Independent Director of Continucare Corporation since January 2004. He served as a Director of PROLOR Biotech, Inc. since May 2007. He served as a Director of North American Vaccine since October 1989, ERBA Diagnostics, Inc., from 2001 to April 2006, Orthodontix Inc., since January 03, 2007, Cellular Technical Services Co. Inc. since April 12, 2005 and Protalix BioTherapeutics, Inc., from December 31, 2006 to December 2007. He served as a Director of Teva Pharmaceutical Industries Limited from 2006 to February 4, 2015. He served as a Director of American Exploration Company from 1983 to 1998 and Northrup Grumman Corporation from 1996 to May 20, 2009. He served as a Director of TransEnterix, Inc. since 2013. He served as a Member of Board of Regents of Smithsonian Institution from 2006 to 2010. He served as a Director of Teva Czech Industries s.r.o. He served as a Director of SafeStitch Medical, Inc., since 2005. He served as a Director of Northrop Grumman Corporation from 1996 to May 20, 2009, Pan Am Corporation since March 8, 1996 and IVAX LLC since 1987. He served as a Director of GBI Capital Management Corp., IVAX-CR AS and IVAX Pharmaceuticals s.r.o. He served as a Director of CoCrystal Discovery, Inc. He served as the Chairman of the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1990. He served as the Chairman of the Board at IVAX LLC from 1987 to January 26, 2006. He served as the Vice Chairman of Cogint, Inc. from December 2015 to March 12, 2018 and as its Director from December 8, 2015 until March 12, 2018. His internship was conducted at the University of Chicago Hospitals and Clinics in Straight Medicine. He attended the University of Paris from 1995 to 1996. Dr. Frost received a B.A. in French Literature from the University of Pennsylvania in 1957 and Doctor of Medicine Degree from the Albert Einstein College of Medicine, New York in 1961.

CEO Compensation
  • Phil's compensation has increased whilst company is loss making.
  • Phil's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the OPKO Health management team in years:

6.1
Average Tenure
64
Average Age
  • The average tenure for the OPKO Health management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Phil Frost

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
83
TENURE
13.1 yrs

Jane Hsiao

TITLE
Vice Chairman & Chief Technical Officer
COMPENSATION
$2M
AGE
72
TENURE
12.9 yrs

Adam Logal

TITLE
Senior VP
COMPENSATION
$1M
AGE
41
TENURE
6.1 yrs

Steve Rubin

TITLE
Executive VP of Administration & Director
COMPENSATION
$1M
AGE
59
TENURE
12.9 yrs

Kate Inman

TITLE
General Counsel & Secretary
AGE
46

Arie Gutman

TITLE
President of API
AGE
65

James DeMarco

TITLE
Senior Vice President of Pharmaceutical Sales
TENURE
4 yrs

Tom Nusbickel

TITLE
Chief Commercial Officer
TENURE
3.9 yrs

Akhtar Ashfaq

TITLE
Senior Vice President of Clinical Research & Development and Medical Affairs
TENURE
3.1 yrs

Jon Cohen

TITLE
Senior Vice President
AGE
64
Board of Directors Tenure

Average tenure and age of the OPKO Health board of directors in years:

12.6
Average Tenure
72
Average Age
  • The average tenure for the OPKO Health board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jane Hsiao

TITLE
Vice Chairman & Chief Technical Officer
COMPENSATION
$2M
AGE
72
TENURE
12.9 yrs

Steve Rubin

TITLE
Executive VP of Administration & Director
COMPENSATION
$1M
AGE
59
TENURE
13.2 yrs

Jon Cohen

TITLE
Senior Vice President
AGE
64
TENURE
1.3 yrs

John Paganelli

TITLE
Independent Director
COMPENSATION
$75K
AGE
84
TENURE
16.3 yrs

Phil Frost

TITLE
Chairman & CEO
COMPENSATION
$2M
AGE
83
TENURE
13.1 yrs

Richard Lerner

TITLE
Independent Director & Member of Scientific Advisory Board
COMPENSATION
$70K
AGE
81

Rick Pfenniger

TITLE
Independent Director
COMPENSATION
$95K
AGE
64
TENURE
12.3 yrs

Robert Fishel

TITLE
Independent Director
COMPENSATION
$112K
AGE
57
TENURE
2 yrs

Alice Yu

TITLE
Independent Director
COMPENSATION
$60K
AGE
75
TENURE
11 yrs

Roger Kornberg

TITLE
Member of Scientific Advisory Board
AGE
72
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by OPKO Health individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Apr 20 Buy Frost Gamma Investments Trust Company 03. Apr 20 03. Apr 20 50,000 €1.08 €53,382
03. Apr 20 Buy Frost Gamma Investments Trust Company 02. Apr 20 02. Apr 20 500,000 €1.09 €534,283
02. Apr 20 Buy Frost Gamma Investments Trust Company 01. Apr 20 01. Apr 20 643,549 €1.15 €725,210
31. Mar 20 Buy Frost Gamma Investments Trust Company 30. Mar 20 30. Mar 20 161,968 €1.22 €197,629
30. Mar 20 Buy Frost Gamma Investments Trust Company 27. Mar 20 27. Mar 20 100,000 €1.26 €126,244
27. Mar 20 Buy Frost Gamma Investments Trust Company 26. Mar 20 26. Mar 20 200,000 €1.26 €249,912
20. Mar 20 Buy Frost Gamma Investments Trust Company 19. Mar 20 19. Mar 20 100,000 €1.40 €139,016
13. Mar 20 Buy Anthony Japour Individual 12. Mar 20 12. Mar 20 500 €1.36 €682
11. Mar 20 Buy Frost Gamma Investments Trust Company 10. Mar 20 10. Mar 20 300,000 €1.46 €425,284
04. Mar 20 Buy Frost Gamma Investments Trust Company 03. Mar 20 03. Mar 20 100,000 €1.32 €131,815
04. Mar 20 Buy Anthony Japour Individual 03. Mar 20 03. Mar 20 500 €1.32 €659
03. Mar 20 Buy Frost Gamma Investments Trust Company 02. Mar 20 02. Mar 20 100,000 €1.34 €133,633
02. Mar 20 Buy Frost Gamma Investments Trust Company 28. Feb 20 28. Feb 20 125,000 €1.33 €165,583
28. Feb 20 Buy Frost Gamma Investments Trust Company 27. Feb 20 27. Feb 20 250,000 €1.38 €336,940
18. Feb 20 Buy Frost Gamma Investments Trust Company 14. Feb 20 14. Feb 20 100,000 €1.46 €145,070
14. Feb 20 Buy Frost Gamma Investments Trust Company 13. Feb 20 13. Feb 20 100,000 €1.46 €145,597
12. Feb 20 Buy Frost Gamma Investments Trust Company 11. Feb 20 11. Feb 20 14,239 €1.46 €20,734
07. Feb 20 Buy Frost Gamma Investments Trust Company 06. Feb 20 06. Feb 20 50,000 €1.39 €69,653
03. Feb 20 Buy Frost Gamma Investments Trust Company 31. Jan 20 31. Jan 20 50,000 €1.29 €64,719
31. Jan 20 Buy Frost Gamma Investments Trust Company 30. Jan 20 30. Jan 20 100,000 €1.34 €133,270
27. Jan 20 Buy Frost Gamma Investments Trust Company 24. Jan 20 24. Jan 20 50,000 €1.43 €71,645
24. Jan 20 Buy Frost Gamma Investments Trust Company 23. Jan 20 23. Jan 20 50,000 €1.48 €73,823
21. Jan 20 Buy Frost Gamma Investments Trust Company 17. Jan 20 17. Jan 20 22,262 €1.41 €31,308
14. Jan 20 Buy Frost Gamma Investments Trust Company 13. Jan 20 13. Jan 20 50,000 €1.29 €64,613
13. Jan 20 Buy Frost Gamma Investments Trust Company 10. Jan 20 10. Jan 20 50,000 €1.33 €66,570
09. Jan 20 Buy Frost Gamma Investments Trust Company 08. Jan 20 08. Jan 20 50,000 €1.32 €66,143
17. Jul 19 Buy Frost Nevada Investments Trust Company 16. Jul 19 16. Jul 19 50,000 €1.89 €94,492
15. Jul 19 Buy Frost Nevada Investments Trust Company 12. Jul 19 12. Jul 19 50,000 €1.94 €95,748
09. Jul 19 Buy Frost Nevada Investments Trust Company 08. Jul 19 08. Jul 19 100,000 €2.02 €198,698
03. Jul 19 Buy Frost Nevada Investments Trust Company 02. Jul 19 02. Jul 19 50,000 €2.14 €106,987
26. Jun 19 Buy Frost Nevada Investments Trust Company 25. Jun 19 25. Jun 19 100,000 €1.78 €176,242
21. Jun 19 Buy Frost Nevada Investments Trust Company 20. Jun 19 20. Jun 19 50,000 €1.82 €90,587
20. Jun 19 Buy Frost Nevada Investments Trust Company 19. Jun 19 19. Jun 19 25,000 €1.79 €44,695
19. Jun 19 Buy Frost Nevada Investments Trust Company 18. Jun 19 18. Jun 19 50,000 €1.81 €90,118
17. Jun 19 Buy Frost Nevada Investments Trust Company 14. Jun 19 14. Jun 19 70,000 €1.72 €119,286
14. Jun 19 Buy Frost Nevada Investments Trust Company 13. Jun 19 13. Jun 19 50,000 €1.72 €85,320
13. Jun 19 Buy Frost Nevada Investments Trust Company 12. Jun 19 12. Jun 19 15,000 €1.61 €24,186
12. Jun 19 Buy Frost Nevada Investments Trust Company 11. Jun 19 11. Jun 19 50,000 €1.65 €82,405
10. Jun 19 Buy Frost Nevada Investments Trust Company 07. Jun 19 07. Jun 19 50,000 €1.66 €82,540
07. Jun 19 Buy Frost Nevada Investments Trust Company 06. Jun 19 06. Jun 19 25,000 €1.70 €42,481
06. Jun 19 Buy Frost Nevada Investments Trust Company 05. Jun 19 05. Jun 19 150,000 €1.73 €256,240
03. Jun 19 Buy Frost Nevada Investments Trust Company 31. May 19 31. May 19 100,000 €1.61 €158,267
31. May 19 Buy Frost Nevada Investments Trust Company 30. May 19 30. May 19 50,000 €1.69 €83,722
30. May 19 Buy Frost Nevada Investments Trust Company 29. May 19 29. May 19 70,000 €1.68 €115,892
29. May 19 Buy Frost Nevada Investments Trust Company 28. May 19 28. May 19 200,000 €1.74 €340,330
24. May 19 Buy Frost Nevada Investments Trust Company 23. May 19 23. May 19 200,000 €1.72 €343,699
23. May 19 Buy Frost Nevada Investments Trust Company 22. May 19 22. May 19 125,000 €1.82 €224,225
20. May 19 Buy Frost Nevada Investments Trust Company 17. May 19 17. May 19 50,000 €1.87 €93,122
17. May 19 Buy Frost Nevada Investments Trust Company 16. May 19 16. May 19 100,000 €1.82 €180,874
15. May 19 Buy Frost Nevada Investments Trust Company 14. May 19 14. May 19 1,000,000 €1.81 €1,779,961
14. May 19 Buy Frost Nevada Investments Trust Company 13. May 19 13. May 19 200,000 €1.78 €354,061
13. May 19 Buy Frost Nevada Investments Trust Company 10. May 19 10. May 19 70,000 €1.87 €129,744
10. May 19 Buy Frost Nevada Investments Trust Company 09. May 19 09. May 19 285,000 €1.89 €521,641
09. May 19 Buy Frost Nevada Investments Trust Company 08. May 19 08. May 19 907,000 €1.99 €1,708,567
23. Apr 19 Buy Frost Nevada Investments Trust Company 22. Apr 19 22. Apr 19 80,000 €2.10 €164,862
18. Apr 19 Buy Frost Nevada Investments Trust Company 17. Apr 19 17. Apr 19 50,000 €2.15 €107,031
17. Apr 19 Buy Frost Nevada Investments Trust Company 16. Apr 19 16. Apr 19 10,000 €2.21 €22,140
16. Apr 19 Buy Frost Nevada Investments Trust Company 15. Apr 19 15. Apr 19 10,000 €2.18 €21,813
15. Apr 19 Buy Frost Nevada Investments Trust Company 12. Apr 19 12. Apr 19 20,000 €2.21 €44,180
12. Apr 19 Buy Frost Nevada Investments Trust Company 11. Apr 19 11. Apr 19 30,000 €2.22 €66,165
11. Apr 19 Buy Frost Nevada Investments Trust Company 10. Apr 19 10. Apr 19 20,000 €2.26 €44,944
10. Apr 19 Buy Frost Nevada Investments Trust Company 09. Apr 19 09. Apr 19 10,000 €2.23 €22,265
31. Dec 19 Buy Frost Gamma Investments Trust Company 30. Dec 19 30. Dec 19 100,000 €1.30 €130,159
30. Dec 19 Buy Frost Gamma Investments Trust Company 27. Dec 19 27. Dec 19 100,000 €1.37 €136,472
18. Dec 19 Buy Frost Gamma Investments Trust Company 17. Dec 19 17. Dec 19 75,000 €1.39 €103,445
20. Dec 19 Buy Frost Gamma Investments Trust Company 19. Dec 19 19. Dec 19 100,000 €1.35 €133,272
19. Dec 19 Buy Frost Gamma Investments Trust Company 18. Dec 19 18. Dec 19 150,000 €1.36 €202,095
12. Dec 19 Buy Frost Gamma Investments Trust Company 11. Dec 19 11. Dec 19 100,000 €1.37 €135,350
10. Dec 19 Buy Frost Gamma Investments Trust Company 09. Dec 19 09. Dec 19 50,000 €1.44 €71,804
06. Dec 19 Buy Frost Gamma Investments Trust Company 05. Dec 19 05. Dec 19 50,000 €1.44 €72,048
04. Dec 19 Buy Frost Gamma Investments Trust Company 03. Dec 19 03. Dec 19 10,286 €1.44 €14,840
03. Dec 19 Buy Frost Gamma Investments Trust Company 02. Dec 19 02. Dec 19 50,000 €1.41 €70,127
27. Nov 19 Buy Frost Gamma Investments Trust Company 26. Nov 19 26. Nov 19 100,000 €1.41 €140,255
20. Nov 19 Buy Frost Gamma Investments Trust Company 19. Nov 19 19. Nov 19 100,000 €1.33 €132,352
19. Nov 19 Buy Frost Gamma Investments Trust Company 18. Nov 19 18. Nov 19 100,000 €1.34 €133,414
14. Nov 19 Buy Frost Gamma Investments Trust Company 13. Nov 19 13. Nov 19 50,000 €1.30 €64,698
13. Nov 19 Buy Frost Gamma Investments Trust Company 12. Nov 19 12. Nov 19 200,000 €1.32 €261,617
12. Nov 19 Buy Frost Gamma Investments Trust Company 08. Nov 19 08. Nov 19 50,000 €1.35 €67,207
07. Nov 19 Buy Frost Gamma Investments Trust Company 06. Nov 19 06. Nov 19 350,000 €1.37 €470,119
01. Nov 19 Buy Frost Gamma Investments Trust Company 31. Oct 19 31. Oct 19 50,000 €1.28 €63,919
31. Oct 19 Buy Frost Gamma Investments Trust Company 30. Oct 19 30. Oct 19 200,000 €1.31 €259,420
30. Oct 19 Buy Frost Gamma Investments Trust Company 29. Oct 19 29. Oct 19 200,000 €1.35 €264,719
28. Oct 19 Buy Frost Gamma Investments Trust Company 25. Oct 19 25. Oct 19 350,000 €1.31 €442,893
25. Oct 19 Buy Richard Pfenniger Individual 25. Oct 19 25. Oct 19 25,000 €1.31 €32,683
25. Oct 19 Buy Steven Rubin Individual 25. Oct 19 25. Oct 19 15,000 €1.35 €20,291
25. Oct 19 Buy Frost Gamma Investments Trust Company 25. Oct 19 25. Oct 19 2,000,000 €1.35 €2,705,400
25. Oct 19 Buy Hsu Gamma Investments, L.P. Company 25. Oct 19 25. Oct 19 400,000 €1.35 €541,080
29. May 19 Buy Robert Fishel Individual 28. May 19 28. May 19 50,000 €1.72 €85,901
23. May 19 Buy Richard Pfenniger Individual 22. May 19 22. May 19 30,000 €1.84 €55,147
14. May 19 Buy Richard Pfenniger Individual 13. May 19 13. May 19 50,000 €1.83 €91,248
10. May 19 Buy Steven Rubin Individual 09. May 19 09. May 19 7,200 €1.91 €13,783
10. May 19 Buy Steven Rubin Individual 09. May 19 09. May 19 2,800 €1.90 €5,309
10. May 19 Buy Jane Hsiao Individual 09. May 19 09. May 19 10,000 €1.82 €18,072
10. May 19 Buy Adam Logal Individual 09. May 19 09. May 19 3,250 €1.82 €5,903
10. May 19 Buy John Paganelli Individual 09. May 19 09. May 19 10,000 €1.86 €18,599
X
Management checks
We assess OPKO Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OPKO Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company’s Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Details
Name: OPKO Health, Inc.
XCY
Exchange: DB
Founded: 1991
$781,096,419
669,828,524
Website: http://www.opko.com
Address: OPKO Health, Inc.
4400 Biscayne Boulevard,
Miami,
Florida, 33137,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS OPK Common Stock Nasdaq Global Select US USD 02. Nov 1995
DB XCY Common Stock Deutsche Boerse AG DE EUR 02. Nov 1995
LSE 0KCS Common Stock London Stock Exchange GB USD 02. Nov 1995
TASE OPK Common Stock The Tel-Aviv Stock Exchange IL ILS 02. Nov 1995
BMV OPK * Common Stock Bolsa Mexicana de Valores MX MXN 02. Nov 1995
Number of employees
Current staff
Staff numbers
6,096
OPKO Health employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:22
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.